Mölnlycke Health Care and Zhende Medical form pioneering joint venture to expand access to advanced wound care solutions in China

Mölnlycke Health Care, a prominent player in the MedTech sector, has announced the formation of a joint venture with Zhende Medical, a leading Chinese supplier of medical care products. This collaboration, named Mölnlycke Zhende (Shanghai) Medical Technology Co Ltd, aims to enhance access to advanced wound care solutions in China. While the specific deal value remains undisclosed, the joint venture is expected to become operational in the third quarter of 2026, targeting nearly 10,000 hospitals and 200,000 pharmacies across the country.

The joint venture will leverage the advanced wound care portfolios of both Mölnlycke and Zhende Medical, combining their strengths to offer a broader range of products and services. Mölnlycke brings over 175 years of innovation in wound care, including its proprietary Safetac® technology, while Zhende Medical contributes its expertise in therapeutic areas such as burns and chronic wound care. This strategic partnership is positioned to capitalize on the rapid growth of China's advanced wound care market, which is currently valued at approximately EUR 380 million (RMB 3 billion). Factors such as an aging population and a rising prevalence of chronic diseases are driving demand for sophisticated treatment solutions.

The formation of Mölnlycke Zhende represents a significant step for both companies in their efforts to expand their market presence in China. For Mölnlycke, this joint venture aligns with its localization strategy, allowing the company to integrate global expertise with local market knowledge. This approach is expected to enhance customer engagement and improve access to advanced wound care solutions tailored to the specific needs of Chinese healthcare providers and patients. Meanwhile, Zhende Medical aims to deepen its collaboration with a global leader, ensuring its product portfolio remains relevant and valuable in a competitive landscape.

As the joint venture prepares for its launch, it will initially focus on the sales and distribution of both companies' advanced wound care products. There is potential for future co-development of new products, further solidifying their market position. The partnership is also committed to adhering to global sustainability standards, reflecting both companies' dedication to responsible business practices.

The establishment of Mölnlycke Zhende is indicative of the growing opportunities within the Chinese healthcare sector, particularly in advanced wound care. As the market continues to evolve, this joint venture may set a precedent for similar collaborations in the industry, highlighting the importance of strategic partnerships in addressing the increasing demand for innovative healthcare solutions. The implications of this venture could resonate beyond the immediate market, influencing future investments and developments in the global MedTech landscape.